Dr. Muss on Determining Treatments for HER2+ Breast Cancer

Hyman B. Muss, MD
Published: Monday, Oct 09, 2017



Hyman B. Muss, MD, professor of medicine, University of North Carolina-Chapel Hill School of Medicine, Breast Cancer Geriatric Oncology Program, director, geriatric oncology, UNC Lineberger Comprehensive Cancer Center, 2017 Giant of Cancer Care in Supportive/Palliative/Geriatric Care, discusses determining treatments for patients with HER2-positive breast cancer.

In the APT trial, patients with HER2-positive breast cancer with smaller node-negative tumors received weekly paclitaxel (Abraxane) and 1 year of trastuzumab (Herceptin). This trial of 400 patients showed 4 relapses with a median follow-up of 6 years. According to Muss, if a patient fits this criteria they should receive this treatment.

If a patient has a more aggressive disease, chemotherapy that omits anthracyclines and regimens that include docetaxel, carboplatin, and trastuzumab should be given.
 


Hyman B. Muss, MD, professor of medicine, University of North Carolina-Chapel Hill School of Medicine, Breast Cancer Geriatric Oncology Program, director, geriatric oncology, UNC Lineberger Comprehensive Cancer Center, 2017 Giant of Cancer Care in Supportive/Palliative/Geriatric Care, discusses determining treatments for patients with HER2-positive breast cancer.

In the APT trial, patients with HER2-positive breast cancer with smaller node-negative tumors received weekly paclitaxel (Abraxane) and 1 year of trastuzumab (Herceptin). This trial of 400 patients showed 4 relapses with a median follow-up of 6 years. According to Muss, if a patient fits this criteria they should receive this treatment.

If a patient has a more aggressive disease, chemotherapy that omits anthracyclines and regimens that include docetaxel, carboplatin, and trastuzumab should be given.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x